Home › Funds › BAKER BROS. ADVISORS LP › MDGL
BAKER BROS. ADVISORS LP position in MDGL
MADRIGAL PHARMACEUTICALS INC · Health Care
BAKER BROS. ADVISORS LP reported holding 2,143,131 shares of MDGL (MADRIGAL PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$1.15B, representing 6.02% of its reported portfolio and ranking #4 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed MDGL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's MDGL position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in MDGL in Q3 2023 at 1,545,113 shares (US$225.6M). The position peaked in Q4 2025 at 2,141,701 shares, worth US$1.25B. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 9 time(s). The most recent filing (Q2 2026) shows 2,143,131 shares valued at US$1.15B. Notable position changes include a 27% increase in Q4 2023 (shares rose 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.55M | $225.65M | New |
| Q4 2023 | 1.97M | $455.77M | Add |
| Q1 2024 | 1.97M | $526.01M | Hold |
| Q2 2024 | 1.97M | $553.20M | Hold |
| Q3 2024 | 1.97M | $419.05M | Hold |
| Q4 2024 | 1.97M | $609.30M | Hold |
| Q1 2025 | 1.97M | $654.04M | Hold |
| Q2 2025 | 1.98M | $598.02M | Hold |
| Q3 2025 | 2.14M | $982.31M | Add |
| Q4 2025 | 2.14M | $1.25B | Hold |
| Q1 2026 | 2.14M | $1.12B | Hold |
| Q2 2026 | 2.14M | $1.15B | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MDGL and 13F data
MDGL (MADRIGAL PHARMACEUTICALS INC) is a Health Care company. 47 other funds we track also report a position in MDGL — the largest reported positions include RTW INVESTMENTS, LP (US$1.07B), Janus Henderson Group (US$1.05B), Jupiter Topco LLC (US$1.04B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MDGL
- RTW INVESTMENTS, LP 1.99M sh · $1.07B · Q2 2026
- Janus Henderson Group 2.02M sh · $1.05B · Q1 2026
- Jupiter Topco LLC 1.94M sh · $1.04B · Q2 2026
- Avoro Capital Advisors LLC 1.83M sh · $984.41M · Q2 2026
- Paulson & Co 1.34M sh · $719.52M · Q2 2026
- PAULSON & CO. INC. 1.34M sh · $719.52M · Q2 2026
- ARMISTICE CAPITAL, LLC 288.00K sh · $154.64M · Q2 2026
- Rock Springs Capital Management LP 175.00K sh · $93.97M · Q2 2026
- Erste Asset Management GmbH 110.21K sh · $58.11M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held MDGL?
BAKER BROS. ADVISORS LP has disclosed MDGL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BAKER BROS. ADVISORS LP's current position in MDGL?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 2.14M shares of MDGL (MADRIGAL PHARMACEUTICALS INC), valued at $1.15B, representing 6.02% of its reported portfolio and ranking #4.
Has BAKER BROS. ADVISORS LP been buying or selling MDGL?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in MDGL. The position peaked in Q4 2025 at 2.14M shares.
Which other funds hold MDGL?
Other major institutional holders of MDGL include RTW INVESTMENTS, LP, Janus Henderson Group, Jupiter Topco LLC, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.